首页> 外文期刊>Pathogens >Rates and Correlates of Short Term Virologic Response among Treatment-Na?ve HIV-Infected Children Initiating Antiretroviral Therapy in Ethiopia: A Multi-Center Prospective Cohort Study
【24h】

Rates and Correlates of Short Term Virologic Response among Treatment-Na?ve HIV-Infected Children Initiating Antiretroviral Therapy in Ethiopia: A Multi-Center Prospective Cohort Study

机译:埃塞俄比亚未接受过艾滋病毒治疗的未接受过艾滋病毒感染的儿童中短期病毒学应答的发生率和相关性:多中心前瞻性队列研究

获取原文
           

摘要

There is limited data on virologic outcome and its correlates among HIV-infected children in resource-limited settings. We investigated rate and correlates of virologic outcome among treatment na?ve HIV-infected Ethiopian children initiating cART, and were followed prospectively at baseline, 8, 12, 24 and 48 weeks using plasma viral load, clinical examination, laboratory tests and pretreatment HIV drug resistance (PDR) screening. Virologic outcome was assessed using two endpoints–virological suppression defined as having “undetectable” plasma viral load 150 RNA copies/mL, and rebound defined as viral load ≥150 copies/mL after achieving suppression. Cox Proportional Hazards Regression was employed to assess correlates of outcome. At the end of follow up, virologic outcome was measured for 110 participants. Overall, 94(85.5%) achieved virological suppression, of which 36(38.3%) experienced virologic rebound. At 48 weeks, 9(8.2%) children developed WHO-defined virological treatment failure. Taking tenofovir-containing regimen (Hazard Ratio (HR) 3.1-[95% confidence interval (95%CI) 1.0–9.6], p = 0.049) and absence of pretreatment HIV drug resistance (HR 11.7-[95%CI 1.3–104.2], p = 0.028) were independently associated with earlier virologic suppression. In conclusion, PDR and cART regimen type correlate with rate of virologic suppression which was prominent during the first year of cART initiation. However, the impact of viral rebound in 38.3% of the children needs evaluation.
机译:在资源有限的环境中,关于病毒学结局及其与HIV感染儿童之间相关性的数据有限。我们调查了初次接受HIV感染的埃塞俄比亚儿童接受治疗的cART初治儿童中病毒学结果的发生率和相关性,并在基线,第8、12、24和48周使用血浆病毒载量,临床检查,实验室测试和HIV预处理药物进行了前瞻性随访耐药性(PDR)筛查。病毒学结果的评估有两个终点:病毒抑制被定义为血浆血浆病毒载量“检测不到” <150 RNA拷贝/ mL,反弹被定义为病毒抑制≥150拷贝/ mL。使用Cox比例危害回归法评估结果的相关性。在随访结束时,对110名参与者进行了病毒学评估。总体而言,有94(85.5%)人获得了病毒学抑制,其中36(38.3%)人受到了病毒学反弹。在第48周,有9名(8.2%)儿童发生了WHO定义的病毒学治疗失败。采取含替诺福韦的方案(危险比(HR)3.1- [95%置信区间(95%CI)1.0-9.6],p = 0.049)和无治疗前HIV耐药性(HR 11.7- [95%CI 1.3-104.2] ],p = 0.028)独立地与较早的病毒学抑制有关。总之,PDR和cART方案类型与病毒抑制率相关,后者在cART启动的第一年就很明显。但是,有38.3%的儿童病毒反弹的影响需要评估。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号